← Eichor
Condition: Non Clear Renal Cell Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Non Clear Renal Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Phase 1/Phase 2 · 4 location(s) · Cancer Research UK · NCT06380816Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Phase 1/Phase 2 · 12 location(s) · GI Innovation, Inc. · NCT04977453Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
Phase 2 · 1 location(s) · Giuseppe Procopio · NCT06302569Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483Ivonescimab in the Treatment of Multiple Advanced Tumors
Phase 2 · 1 location(s) · Fudan University · NCT06683846A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcin
Phase 1 · 1 location(s) · PeptiDream Inc. · NCT0768818789Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
Phase 3 · 8 location(s) · Telix Pharmaceuticals (Innovations) Pty Limited · NCT06750419KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Phase 1 · 38 location(s) · Kura Oncology, Inc. · NCT06026410Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Phase 2 · 6 location(s) · M.D. Anderson Cancer Center · NCT06053658Agnostic Therapy in Rare Solid Tumors
Phase 2 · 8 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06638931A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Pliant Therapeutics, Inc. · NCT0627070618F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
NA · 1 location(s) · Peking University First Hospital · NCT07557225Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 · 22 location(s) · Incyte Corporation · NCT07195916Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Phase 1 · 7 location(s) · Sairopa B.V. · NCT05856981Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors
Phase 2 · 2 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT05768464Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1 · 3 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT07517198A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129CD70-targeted immunoPET Imaging of Malignant Cancers
Phase 2 · 1 location(s) · RenJi Hospital · NCT06852638Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Phase N/A · 3 location(s) · Mayo Clinic · NCT06349642Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Ce
Phase 1 · 11 location(s) · Neomorph, Inc · NCT07300241Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carci
Phase 2 · 3 location(s) · Qian Qin · NCT06794229
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.